NanoViricides, Inc. (NNVC) financial statements (2021 and earlier)

Company profile

Business Address 1 CONTROLS DRIVE
SHELTON, CT 06484
State of Incorp. NV
Fiscal Year End June 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
TTM
6/30/2020
6/30/2019
6/30/2018
6/30/2017
6/30/2016
6/30/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments181437152431
Cash and cash equivalents181437152431
Prepaid expense0000000
Total current assets:181437152432
Noncurrent Assets
Property, plant and equipment9101011111212
Intangible assets, net (including goodwill)0000000
Intangible assets, net (excluding goodwill)0000000
Other undisclosed noncurrent assets0000000
Total noncurrent assets:10101111121213
TOTAL ASSETS:28241319273744
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities0000000
Accounts payable0000000
Accrued liabilities0000000
Interest and dividends payable    000
Debt     5 
Derivative instruments and hedges, liabilities     0 
Due to related parties0110010
Other undisclosed current liabilities 1204  
Total current liabilities:0231571
Noncurrent Liabilities
Other undisclosed noncurrent liabilities    2712
Total noncurrent liabilities:    2712
Total liabilities:023171412
Stockholders' equity
Stockholders' equity attributable to parent, including:28221118202332
Common stock0000000
Additional paid in capital138127103101958886
Accumulated deficit(110)(106)(92)(84)(75)(65)(54)
Other undisclosed stockholders' equity attributable to parent0000000
Total stockholders' equity:28221118202332
TOTAL LIABILITIES AND EQUITY:28241319273744

Income statement (P&L) ($ in millions)

12/31/2020
TTM
6/30/2020
6/30/2019
6/30/2018
6/30/2017
6/30/2016
6/30/2015
Operating expenses(9)(8)(9)(9)(10)(9)(7)
Operating loss:(9)(8)(9)(9)(10)(9)(7)
Nonoperating income (expense)(6)(5)01(1)(2)5
Other nonoperating income000000 
Interest and debt expense(0)(0) (0)(0)(1)(3)
Loss from continuing operations before equity method investments, income taxes:(15)(14)(8)(9)(11)(12)(5)
Other undisclosed income from continuing operations before income taxes00 0013
Net loss available to common stockholders, basic:(15)(13)(8)(9)(10)(11)(2)
Dilutive securities, effect on basic earnings per share      (3)
Net loss available to common stockholders, diluted:(15)(13)(8)(9)(10)(11)(5)

Comprehensive Income ($ in millions)

12/31/2020
TTM
6/30/2020
6/30/2019
6/30/2018
6/30/2017
6/30/2016
6/30/2015
Net loss:(15)(13)(8)(9)(10)(11)(2)
Comprehensive loss, net of tax, attributable to parent:(15)(13)(8)(9)(10)(11)(2)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: